Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors

BOSTON, Sept. 11, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics company, today announced the appointment of Jennifer Good to the Company's Board of Directors. Ms. Good will serve as a member of both the Audit Committee and Compensation Committee.

"We are excited to have Jennifer join the Juniper team. She is an industry veteran with executive operational experience. With her expertise in financial leadership, she brings to our Board a track record of setting and executing on business and financial strategies and is skilled at identifying and negotiating value-creating partnerships and collaborations.  In addition, with her background as both a CEO and CFO, Jennifer is also particularly well-qualified to join our Audit Committee. We look forward to her contributions as we work to achieve our corporate goals," said Alicia Secor, Juniper's President and CEO.

Ms. Good is the co-founder, president, and chief executive officer at Trevi Therapeutics, a late-stage clinical development company. Prior to founding Trevi, she served as president and chief executive officer and as chief financial officer at Penwest Pharmaceuticals, where she successfully led the transition of Penwest Pharmaceuticals from a development stage company to a profitable commercial stage company generating annual revenues in excess of $50 million and negotiating the sale of the Company to its major partner.

Additionally, upon recommendation of the Nominating and Corporate Governance Committee, Juniper's Board of Directors has accepted Dr. Frank Armstrong's notice of resignation, effective September 28, 2017. Dr. Armstrong will step down from all Board committees effective immediately. Director Ann Merrifield will now serve as chair of the Company's Compensation Committee and will step down from her role on the Company's Audit Committee. Cristina Csimma will now serve as a member of the Company's Nominating and Corporate Governance Committee in addition to her current role with the Company's Compensation Committee.

"During his tenure, Frank has made many valuable contributions across numerous aspects of our business and we are grateful for his service to the Company. We would like to thank Frank for sharing with Juniper his wealth of development and management experience and allowing us to benefit from his advice and counsel. We wish him well in his future endeavors," added Ms. Secor.

About Juniper Pharmaceuticals   
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the CRINONE^® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE^® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S. 

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the strength of Juniper's business, product candidates and future results.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  These risks and uncertainties include, but are not limited to: risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process; the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch, if such product candidates are approved; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Juniper Pharmaceuticals' ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from currently approved therapies and from other companies developing products for similar uses; risk associated with Juniper Pharmaceuticals' ability to manage operating expenses and/or obtain additional funding to support its business activities; and risks associated with Juniper Pharmaceuticals' dependence on third parties.  For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2016 and subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

Investor Contact:   
Argot Partners
Laura Perry or Heather Savelle
212-600-1902
[email protected] 
[email protected]

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.   
Follow us on LinkedIn.

SOURCE Juniper Pharmaceuticals, Inc.

Related Links

http://www.juniperpharma.com